The O-glycosylation sites for equine LH␤ (eLH␤) and eCG␤ were identified by solid-phase Edman degradation of four glycopeptides derived from the C-terminal region. Both subunits were O-glycosylated at the same 12 positions, rather than the 4-6 sites anticipated. These sites were partially glycosylated, with carbohydrate attachment ranging from 20% to 100% for eCG␤ and from 10% to 100% for eLH␤. When the C-terminal peptide containing all but one of the O-linked oligosaccharides was removed by mild acid hydrolysis of either eLH␤ or eCG␤, hybrid hormones could be obtained by reassociating eLH␣, eFSH␣, or eCG␣ with the truncated ␤ subunit derivatives. These hybrid hormones were identical in LH receptor-binding activity when des(121-149)eLH␤ or des(121-149)eCG␤ were combined with the same ␣ subunit preparation. Thus, O-glycosylation appears to be responsible for the ␤ subunit contribution to the substantial difference in LH receptor-binding activity between eLH and eCG. Comparison of the equid LH/CG␤ sequences with those available for the primate CG␤ subunits indicated a greater conservation of glycosylation patterns in the former.
INTRODUCTION
A unique structural feature of primate chorionic gonadotropins and equid LH (eLH)/chorionic gonadotropins is an O-glycosylated C-terminal extension of the ␤ subunit that appears to extend survival of these hormones in the circulation but seems to have little to do with cellular activation [1] . Deletion of the C-terminus from eLH␤ and hCG␤ by mild acid hydrolysis [2, 3] or by mutation of recombinant hCG␤ [4, 5] produced no significant effect on LH receptor binding or in vitro biological activity. The potential role of the C-terminal extension in extending circulatory survival was demonstrated by adding it to recombinant bovine LH␤ and recombinant human FSH subunits and noting the decreased metabolic clearance rates of the resulting LH and FSH derivatives [6, 7] . Recently, however, a series of eCG glycosylation isoforms were described that exhibited the same patterns of N-glycosylation but differed in their ␤ subunit O-glycosylation [8] . The most heavily O-glycosylated eCG isoform was significantly less active than the other two eCG isoforms in terms of LH receptor-binding activity. Studies involving hybrid hormone preparations composed of all possible combinations of equine gonado-1 This work was supported by NIH grants AG15428 and DK52383. tropin subunits have demonstrated that both ␣ and ␤ subunits contributed to the difference in receptor-binding affinity between eLH and eCG [9] . The ␣ subunit contribution was largely due to the addition of a Man(␣1-6)Man branch to asparagine (Asn) 56 oligosaccharides and its extension by addition of lactosamine repeats. The ␤Asn 13 oligosaccharides have been reported to consist of largely biantennary structures that were terminated with GalNAc sulfate in eLH␤ and sialylated galactose in eCG␤ [10] [11] [12] . Because these structural differences were unlikely to be responsible for the reduced activity of eCG in vitro and its extended survival in vivo, we began to characterize the O-glycosylation of both eLH and eCG. In terms of O-glycosylation, the eCG␤ C-terminal extension possessed a greater carbohydrate content than that of eLH␤ [13] . It is not known whether this resulted from glycosylation of more of the five threonine (Thr) or 11 serine (Ser) residues located in the C-terminal extension, a greater percentage of carbohydrate present at the same sites, larger oligosaccharides attached to the same sites, or all three factors. Unlike N-glycosylation, which occurs at the consensus motif Asn-Xaa-Thr/Ser (Xaa is any amino acid other than proline), several O-glycosylation motifs have been suggested [14] . The existence of at least six mammalian GalNAc-transferases [15] makes it unlikely that O-glycosylation can be predicted with the same level of confidence as N-glycosylation. Accordingly, we identified the O-glycosylation sites for eLH␤ and eCG␤ using solid-phase Edman degradation.
MATERIALS AND METHODS

Hormone and Subunit Preparations
The equine gonadotropins eLH, eCG, and eFSH and their subunits were prepared by standard isolation procedures [8, 16, 17] . The laboratory eLH reference preparation potency was 2.0ϫ NIDDK-oLH-26 in a rat testis LH receptor binding assay using 125 I-hCG tracer. The eCG preparation employed for identification of the O-glycosylation sites consisted of a mixture of the two most abundant eCG isoforms, eCG-M and eCG-H [8] . These eCG isoforms possessed identical patterns of ␣ subunit N-glycosylation but differed in the sizes of their ␤ subunits because of differential O-glycosylation. However, because the masses of the eCG␤ subunits were very broadly distributed, the imprecise terms low (L), medium (M), and high (H) have been employed to describe eCG preparations possessing ␤ subunits that migrated as broad bands of 71 000-217 000 M r , 61 000-123 000 M r , and 56 000-110 000 M r , respectively. Truncated des(121-149)eLH␤ and des(121-149)eCG␤ derivatives (eLH␤t and eCG␤t, respectively) were produced by mild acid hydrolysis as described previously [3, 9] . These derivatives were combined with eLH␣, eFSH␣, and eCG␣ preparations as described below. The C-terminal peptide byproducts of these ␤ subunit derivatives, which corresponded to CTP-121-149, were used to identify O-glycosylation sites.
Preparation of eLH␤t and eCG␤t Hybrids
We combined 1 mg of eLH␣, eFSH␣, or eCG␣ with 1 mg eLH␤t in 1 ml 0.5 M Tris-acetate buffer, pH 7.0, for 72 h at 37ЊC. The extended incubation period was necessary because eFSH subunits reassociated more slowly than eLH subunits (unpublished data) and eCG subunits reassociated less efficiently [9] . Reassociation buffer was replaced with 0.126 M ammonium bicarbonate by ultrafiltration in a Centricon P-10 (Amicon, Millipore, Bedford, MA), and protein was recovered by vacuum drying in a SpeedVac (Savant, Holbrook, NY). The protein fractions were dissolved in 200 l of 0.126 M ammonium bicarbonate, and chromatography was performed on a Superdex 75 column (Pharmacia, Piscataway, NJ) equilibrated with the same buffer at a flow rate of 0.4 ml/min. Fractions were collected by hand, and protein was recovered by vacuum drying.
LH Receptor Binding and Steroidogenic Activities of Truncated ␤ Subunit Dervatives
The LH receptor binding activity was determined using 125 I-hCG tracer and rat testis homogenate as previously described [8] . A 10-g sample of hCG was iodinated by the chloramine-T method to a specific activity of 49 Ci/g. The 125 I-hCG was diluted to a final concentration of 25 ng/ ml and stored at 4ЊC. Duplicate doses of hormone in 100 l of RLA buffer (0.1 M Tris HCl, pH 7.4, 0.02% sodium azide, and 0.1% BSA) were added to pairs of 12-ϫ 75-mm polypropylene tubes containing 100 l of RLA buffer. A 2.5-ng sample of 125 I-hCG in 100 l of RLA buffer was added to each tube. Receptor preparation, consisting of 25 mg of rat testis homogenate suspended in 200 l of RLA buffer, was added to each tube immediately before incubation. The assay tubes were vortexed and then placed in a shaking water bath and incubated for 2 h at 37ЊC. Following incubation, the tubes were centrifuged at 4600 ϫ g for 30 min at 4ЊC in the H6000 rotor of an RC-3B centrifuge (Sorvall, Newtown, CT). The supernatants were aspirated, and the pellets were counted in a Cobra II gamma counter (Packard, Meriden, CT). A semilogarithmic plot of the percentage of specific binding versus hormone concentration was generated with the software package DeltaGraph (SPSS, Chicago, IL). The dose-response curves were simultaneously fitted to a four-parameter logistic equation using a Macintosh implementation of Allfit [18] called MacAllfit, running on a Macintosh IIci computer (Apple, Cupertino, CA). The 50% inhibitory concentrations, relative potencies, and their standard errors were calculated by MacAllfit for each curve. The 95% confidence limits were determined from these data. The within-assay variability was Ͻ5%, and the between-assay variability was Ͻ15%.
The in vitro biological activity of LH was determined in a rat testis Leydig cell bioassay [19, 20] . In a typical assay, two 50-to 80-day-old male rats were killed, and their testes were removed and decapsulated. The testes were placed in a 50-ml plastic culture tube containing 5 mg type I collagenase (Sigma Chemical Co., St. Louis, MO) dissolved in 20 ml of minimum essential medium (MEM; Gibco-BRL, Bethesda, MD). The tube was placed longitudinally in a shaking water bath and incubated for 10 min at 37ЊC with gentle agitation (75 cycles/min). Following incubation, 15 ml of cold MEM was added, and the tube inverted 50 times and then allowed to stand at 4ЊC for 5 min. The supernatant, which contained the Leydig cells, was transferred to a clean 50-ml culture tube. An additional 15-ml aliquot of MEM was added to the pellet, and the process was repeated. The second supernatant fraction was combined with the first, and the combined sample was centrifuged at 160 ϫ g for 10 min at 4ЊC. The supernatant was discarded, the Leydig cell pellet was resuspended in 30 ml of cold MEM, and centrifugation was repeated. The cells were resuspended in cold MEM, and the open tube was placed in a 34ЊC shaker bath and incubated for 1 h with slow (75 cycles/min) shaking. Following the preincubation step, the cells were centrifuged at 160 ϫ g for 10 min at 4ЊC. The cell pellet was resuspended in 25ЊC MEM and diluted to a final concentration of 60 000 cells/200 l. Triplicate hormone samples that had been diluted in 100 l MEM were combined with 200 l of Leydig cell suspension in 12-ϫ 75-mm polypropylene test tubes. The tubes were incubated at 34ЊC for 3 h with gentle shaking (75 cycles/min) and then frozen. On the following day, the tubes were thawed and centrifuged, and the testosterone content of each supernatant was determined by RIA [21] . Antiserum for the testosterone RIA was obtained from Dr. Gordon Niswender (Colorado State University, Ft. Collins, CO). RIA data were analyzed using the software package AssayZap (Biosoft, Ferguson, MO). The within-assay variability and between-assay variability for the testosterone RIA were Ͻ10% and Ͻ12%, respectively. The Leydig cell assay dose-response curves were plotted using DeltaGraph, and statistical analysis was carried out using MacAllfit [18] . Relative potencies and 95% confidence limits were determined from the results of this analysis.
Isolation of C-Terminal Peptides CTP-100-149, CTP-121-149, and CTP-140-149 A 9.4-mg sample of reduced, carboxymethylated (RCM)-eCG␤ was dissolved in 0.05 M sodium phosphate buffer, pH 7.8, and incubated for 24 h in the presence of 2% Staphylococcus aureus V8 protease [22] . An 11.8-mg sample of RCM-eLH␤ was digested with V8 protease using the same conditions. A fraction consisting of two O-glycosylated peptides was separated from the N-glycosylated amino terminal glycopeptide fraction by gel filtration over Sephacryl S-200, as previously described [22] . The Olinked glycopeptides were identified by automated Edman degradation using an updated 890B sequencer (Beckman, Fullerton, CA) [22] . The larger glycopeptide (residues 62-149) was separated from the shorter form (residues 100-149) by reverse-phase HPLC using a Vydac C-18 column (The Separations Group, Hesperia, CA) attached to an HPLC system (Waters, Milford, MA) as previously described [22] . The column was equilibrated with 0.01% trifluoroacetate (TFA) in water at a flow rate of 1 ml/min. Samples consisting of the C-terminal glycopeptide fractions derived from either eLH or eCG were dissolved in the 0.01% TFA and applied to the column. The column was washed with 0.01% TFA in water for 5 min. Following the wash, the eluant composition was changed to 5% acetonitrile for eLH␤ peptides and 9% acetonitrile for eCG␤ peptides in a stepwise manner. A linear gradient to 35% acetonitrile applied over the next 80 min developed the chromatogram. A stepwise increase to 80% acetonitrile for 10 min followed by a 10-min re-equilibration period with 0.01% TFA/water completed the chromatogram. The absorbance at 214 nm was monitored, and peptide fractions were collected by hand and dried under vacuum in a SpeedVac. The shorter peptide, designated CTP-100-149, was subjected to carbohydrate composition analysis and solid-phase N-terminal sequencing.
The longer peptide, CTP-62-149, was cleaved by mild acid hydrolysis to obtain CTP-121-149. CTP-62-149 was dissolved in 0.013 N HCl and incubated at 110ЊC for 30 min [13] . The sample was applied to a Vydac C-18 column coupled to a different HPLC system (Waters) that consisted of two model 501 HPLC pumps, an automated gradient controller, a U6K sample injector, and a model 484 tunable absorbance monitor. Data were acquired and processed using Maxima software (Waters) running on a PowerMate I computer (NEC, Boxborough, MA). The Vydac C-18 column was equilibrated with 0.01% TFA/water at a flow rate of 1 ml/min. The glycopeptides resulting from mild acid hydrolysis were separated from each other using the same 0-50% acetonitrile gradient employed to separate CTP-121-149 from the ␤ core fragment of eLH␤ or eCG␤ [13] .
We obtained a third glycopeptide, designated CTP-140-149, by tryptic digestion of the intact ␤ subunit preparations following an approach previously reported for eLH␤ [22] . Samples consisting of either 1.1 mg intact eLH␤ or 1.1 mg intact eCG␤ were incubated in 0.1 M ammonium bicarbonate buffer, pH 7.8, containing 1% (w/w) trypsin at 37ЊC for 4 h. Glycopeptides were separated from the eLH␤ core fraction by reverse-phase HPLC using a Vydac C-18 column equilibrated with 0.01% TFA/water at 1 ml/min. The chromatogram was developed with a 0-30% acetonitrile gradient over 50 min as previously described [22] . Digestion of the eCG␤ fraction was repeated with 10% (w/w) trypsin at 37ЊC for 48 h, and the products were chromatographed under the same conditions. Peptide fractions were characterized by amino acid analysis and N-terminal sequencing. Based on results of these preliminary experiments, a 10-mg sample of eLH␤ was digested with trypsin, and the glycopeptides were isolated by reverse-phase HPLC. A fraction consisting of purified CTP-140-149 was coupled to Sequelon-aryl amine (AA) and sequenced. CTP-140-149 could not be obtained from eCG␤.
Identification of O-Glycosylation Sites by Covalent Edman Degradation
O-glycosylation sites were identified by covalent sequencing [14] . Glycopeptides were coupled either to Sequelon-diisothiocyanate (DITC) or Sequelon-AA membranes (Millipore, Bedford, MA) and subjected to automated Edman degradation using a MilliGen model 6600 ProSequencer (Millipore). In initial experiments, a model 600 HPLC system (Waters), including a model 890 multiwavelength absorbance monitor, was employed to monitor the HPLC effluent simultaneously at two wavelengths. The absorbance at 269 nm was used to detect most phenylthiohydantoin (ϾPhNCS) derivatives, and absorbance at 313 nm was employed to detect the dehydro derivatives of ϾPhNCS-Thr and ϾPhNCS-Ser. In later experiments, a model 625 HPLC system (Waters) was employed, which included a model 486 tunable absorbance detector. A composite chromatogram was obtained in this manner. During most of the chromatogram, the absorbance at 269 nm was monitored, except between 10.8 and 11.35 min, when the wavelength was changed to 313 nm to monitor the dehydro derivatives of ϾPhNCS-Thr and ϾPhNCS-Ser.
Estimation of O-Glycosylation Site Occupancy by Carbohydrate Composition Analysis
Because the recoveries of ϾPhNCS-Thr and ϾPhNCS-Ser were very low during automated Edman degradation [23] , it was necessary to measure the carbohydrate or the glycosylated ϾPhNCS-Thr/Ser derivatives to estimate the degree of occupancy at each O-glycosylation site. When we measured the carbohydrate released during automated Edman degradation, we found that it was released at each cycle regardless of whether it was a potential glycosylation site. Better results were obtained when we measured the carbohydrate associated with glycosylated ϾPhNCS-amino acid derivatives. Samples coupled to either Sequelon-DITC or Sequlelon-AA membranes were subjected to automated Edman degradation as described above. We collected portions of the ϾPhNCS-amino acid chromatogram corresponding to the breakthrough fraction (3.5-4.5 min) and the interval (6-9 min) where glycosylated ϾPhNCS-Thr and ϾPhNCS-Ser derivatives were eluted in 10-ϫ 75-mm hydrolysis tubes. The volatile HPLC solvent consisting of 0.035 M ammonium acetate, pH 4.9, and 31-48% acetonitrile was removed under vacuum. Aliquots (200 l) of 4 N TFA were added to each tube, the tubes were sealed, and the contents were hydrolyzed for 4 h at 100ЊC. Following hydrolysis, the tubes were opened and dried under vacuum. Hydrolysates were dissolved in 25 l of water, and 20-l samples were subjected to neutral and amino sugar analysis using a carbohydrate analyzer/ion chromatograph (Dionex, Sunnyvale, CA) [24] . The total galactosamine value was divided by the expected yield of Ser or Thr, based on the repetitive yield determined for the sequencer experiment. We also calculated the extent of glycosylation using the ϾPhNCS-amino acid chromatography data alone according to the method of Pisano et al. [25] . The combined areas of the two ϾPhNCS-Ser peaks or the four ϾPhNCS-Thr peaks were multiplied by 1.25 and then normalized to the ϾPhNCS-valine peak in the standard chromatogram. The amount of glycosylated amino acid derivative was divided by the expected amount of Ser or Thr. The repetitive yield calculated for the sequencer experiment was used to estimate the expected yield at each cycle. We employed the published conversion factor because partial glycosylation was the norm for the equine gonadotropins; therefore, our samples did not provide 100% glycosylated Thr and Ser residues that could be employed to calculate our own conversion factors.
RESULTS
Preparation of eLH/CG␤t Hybrids
Equine ␣ subunit preparations were combined with truncated ␤ subunit derivatives, eLH␤t and eCG␤t, and the heterodimer fractions were separated from unassociated subunit fractions by Superdex 75 chromatography. Purification of eLH␤t hybrids is illustrated in Figure 1 . Based on relative peak heights, the proportion of the unnassociated subunit fraction in the reassociation mixture increased from 14% to 24% as the carbohydrate content of the ␣ subunit increased from 28% for eLH␣ to 41% for eCG␣. The heterodimer peak constituted 60-72% of the total material in the chromatogram, which was comparable to results obtained following association of eLH␣ with intact eLH␤ and was more efficient than associating eFSH␣ or eCG␣ with intact eLH␤ in a previous study [9] . Because the other components were removed by the chromatographic procedure, we were able to eliminate the effect of subunit association efficiency on biological activity determinations.
LH Radioligand and Leydig Cell Bioassay
Intact eCG-L, the most active eCG preparation available for these studies [8] , exhibited only 13% as much rat LH receptor-binding activity as eLH ( Fig. 2A and Table 1 ). The intact eLH␤ hybrids were all less active than intact eLH because of the inactive, unassociated eLH␤ present in each hybrid preparation [26] . The highest LH receptor-binding activity was exhibited by eLH␣:eLH␤ (0.6 ϫ eLH). Although eFSH␣:eLH␤ was less active than eLH␣:eLH␤, it was more active than eCG␣:eLH␤, which had lower activity than eCG-L. Elimination of the C-terminal extension permitting separation of the heterodimer fraction from unassociated subunits revealed the impact of the ␤ subunit. The intact eCG␤ subunit produced a 50% reduction in the LH receptor-binding activity of eCG-L as compared with eCG␣:eCG␤t. The fact that the eCG␣:eLH␤t preparation was more active than eCG-L indicated that the eCG␤ C-terminal extension also contributed to the reduced LH receptor binding of eCG.
A progressive decrease in LH receptor-binding activity associated with increasing size of ␣ subunit oligosaccharide was observed for both sets of truncated ␤ subunit hybrids. The eLH␣:eLH␤t preparation was 0.8 ϫ that of eLH and was more active than eFSH␣:eLH␤t, which was more active than eCG␣:eLH␤t. The same pattern of ␣-specific reduced LH receptor-binding activity was observed with trun- cated eCG␤ hybrids. The most active eCG␤t preparation was eLH␣:eCG␤t, which was more active than intact eLH itself, followed by eFSH␣:eCG␤t and eCG␣:eCG␤t. Whenever the same ␣ subunit preparation was combined with either eLH␤t or eCG␤t, the resulting hybrids exhibited very similar LH receptor-binding activities. The most potent hybrid hormone preparations were eLH␣:eLH␤t and eLH␣: eCG␤t; their inhibition curves bracketed that of eLH. The eFSH␣:eLH␤t and eFSH␣:eCG␤t were the next most active preparations, and the eCG␣:eLH␤t and eCG␣:eCG␤t hybrids were the least active. Thus, removal of the O-glycosylated C-terminal extension from both eLH␤ and eCG␤ virtually eliminated the receptor-binding differences between hormone preparations possessing either of the truncated ␤ subunit preparations and the same ␣ subunit preparation. The LH activities of intact eLH␤ hybrids (Fig. 2B ) and truncated eCG␤t hybrids (Fig. 2C) were compared with that of intact eLH in the rat testis Leydig cell assay. Insufficient amounts of truncated eLH␤t hybrids remained due to extensive testing in rat, human, and chicken FSH receptorbinding assays [9] . Comparing the LH receptor binding ID 50 values with the steroidogenic EC 50 values, the hybrids showed Ͼ100-fold amplification of the steroidogenic response, indicating that fully functional LH hybrids had been prepared in each case. There was no difference in the steroidogenic potencies of the intact eLH␤ hybrids. For the truncated eCG␤t hybrids, both eLH␣:eCG␤t and eFSH␣: eCG␤t were as active as eLH ( Table 1) . The third hybrid, eCG␣:eCG␤t, exhibited a little more than half the activity of these preparations, consistent with its reduced LH receptor-binding activity.
Isolation and Characterization of O-Glycosylated Peptides
Identification of the O-glycosylation sites in eLH␤ and eCG␤ involved isolation and solid-phase Edman degradation of a series of progressively shorter C-terminal glycopeptides, beginning with a 50-amino acid residue peptide that possessed all of the O-glycosylation sites. Results of peptide isolation from RCM-eLH␤ are illustrated in Figure  3 , and similar results were obtained with RCM-eCG␤. Sephacryl S-200 chromatography following V8 protease digestion of an intact RCM-eLH␤ preparation under conditions permitting cleavage at both aspartic acid and glutamic acid residues [27] yielded the expected broad peak containing the O-glycosylated peptide fraction [22] . However, Nterminal sequence determination revealed that this fraction contained two peptides, CTP-62-149 and CTP-100-149. These peptides were separated by reverse-phase HPLC (Fig. 3B) . Purified CTP-100-149 was used to characterize glycosylation of the sequence Ser 115 -Ser 116 -Ser 117 -Ser 118 . CTP-62-149 was subjected to mild acid hydrolysis, and the resulting fragments were separated by reverse-phase HPLC (Fig. 3C) . Fraction A consisted of carbohydrate released by the hydrolysis procedure, and CTP-121-149 was recovered from fraction B. We attempted to obtain a tryptic C-terminal decapeptide by digestion of intact eLH␤ and eCG␤ to assess glycosylation of Thr 148 -Ser 149 (Fig. 4) . This approach was successfully applied to eLH␤; however, eCG␤ was resistant even to prolonged digestion with 10% (w/w) trypsin (Fig. 4C) . The dipeptide Thr 148 -Ser 149 was released from DITC-coupled eCG␤ CTP-121-149 by automated Edman degradation as described in Materials and Methods.
Carbohydrate composition analysis of eLH␤ and eCG␤ CTP-100-149 glycopeptides suggested glycosylation at five sites based on 4.7 mol galactosamine/mol eCG␤ CTP-100-149, whereas the 2.4 mol galactosamine/mol glycopeptide composition of eLH␤ CTP-100-149 indicated only three glycosylation sites ( Table 2 ). The very high galactose and galactosamine content of the eCG␤ CTP-100-149 preparation was consistent with the presence of lactosamine repeats, although the sialic acid content was lower than expected for branched disialylated structures that have been reported [28] . Mild acid hydrolysis of CTP-62-149 quantitatively removed sialic acid, as reported previously [3] . This removal appeared in the breakthrough fractions following reverse-phase HPLC along with other portions of the oligosaccharide. Fifty-four percent of the galactose and 66% of the glucosamine but only 5% of the galactosamine recovered from the eCG␤ CTP-121-149 chromatogram were found in the 4 N TFA hydrolysate of this fraction, suggesting that the lactosamine repeats present in eCG␤ O-linked oligosaccharides [28] were also acid labile. The carbohydrate compositions for CTP-121-149 obtained from eCG␤ revealed that half the galactose and glucosamine and all of the sialic acid were absent. The reduction of galactosamine occurred to a lesser extent but suggested the loss of one glycosylation site. Elimination of one glycosylation site in eLH␤ was also indicated by comparing the galactosamine composition of eLH␤ CTP-100-149 with that of CTP-121-149. The composition of eLH␤ CTP-140-149 reflected that of a single glycosylation site.
Glycosylation of individual Ser and Thr residues was evaluated by solid-phase Edman degradation and carbohydrate composition analysis as described in Materials and Methods. Glycosylated ϾPhNCS-Ser was indicated by two peaks that emerged before ϾPhNCS-Ser itself (Fig. 5) . These peaks were absent from ϾPhNCS chromatograms associated with nonglycosylated Ser residues, as previously reported [29] . Glycosylated Thr residues yielded four peaks that emerged ahead of ϾPhNCS-Thr. The ϾPhNCS-Thr chromatograms for eLH␤ Thr residues 127 and 133 differed from the corresponding Thr residues in eCG␤ by the shoulders associated with the first two peaks (compare Fig. 5, A  and B) . It is not known what oligosaccharide structural feature was associated with these additional peaks; however, it was absent from eLH␤ Thr residues 129 and 131 (data not shown).
Analysis of CTP-100-149 revealed that only Ser 118 in the conserved sequence Ser 115 -Ser 116 -Ser 117 -Ser 118 was glycosylated. For technical reasons, it was not possible to estimate the extent of glycosylation of this Ser residue. However differences in carbohydrate composition between CTP-100-149 and CTP-121-149 suggested 100% carbohydrate occupancy of this site, and the complete resistance of Lys 119 to tryptic digestion provided additional support for this conclusion. Partial glycosylation of most Thr and Ser residues was observed with CTP-121-149. Quantitative analysis of O-glycosylation using the glycosylated ϾPh-NCS amino acid derivative peaks or the galactosamine obtained from hydrolysates of the same region of the ϾPhNCS chromatograms during extensive analysis of CTP-121-149 preparations provided comparable results in most cases (Fig. 6 ). Larger variations in galactosamine recoveries were associated with apparent differences in average glycosylation estimates. These values ranged from 10% to 77% for eLH␤ and from 20% to 100% for eCG␤. The most heavily glycosylated segment of eLH␤ consisted of Thr 127 -Thr 131 , which was also heavily glycosylated in eCG␤. eCG␤ was also heavily glycosylated at Ser 140 -Ser 141 , consistent with its resistance to prolonged tryptic digestion.
Analysis of the glycosylation status at the C-terminal ends required different strategies for each protein. We were able to isolate a decapeptide released by tryptic digestion of an intact eLH␤ preparation. Sequence analysis of CTP-140-149 recovered from fraction 7 (Fig. 4A) indicated the absence of glycosylated Ser residues at the N-terminus, the absence of glycosylation at Thr 148 , and the presence of carbohydrate at Ser 149 , and composition analysis indicated 80% glycosylation of Ser 149 (Table 2 ). This experiment was repeated on a larger scale, and although the CTP-140-149 preparation recovered from fraction 10 (Fig. 4A, inset ) was glycosylated at both Ser 140 and Ser 148 , the absence of glycosylated Thr 148 was confirmed (Fig. 7) . To complete the analysis of eCG␤, we obtained the C-terminal dipeptide Thr 148 -Ser 149 by Edman degradation of CTP-121-140. Man- Figure 4A (inset) was coupled to a Sequelon-AA membrane and subjected to 10 cycles of solid-phase Edman degradation. Chromatograms for the four hydroxy-amino acids found in this peptide are shown. Glycosylated Ser 149 was indicated by a single peak instead of the usual pair of peaks (arrow).
ual Edman degradation of the dipeptide revealed no glycosylated ϾPhNCS-Thr following the first degradation cycle, but glycosylated ϾPhNCS-Ser was observed following the second cycle (data not shown).
DISCUSSION
Increased LH receptor-binding activity of eCG hybrid hormone preparations possessing a truncated eCG␤ subunit differed from results reported for similar modifications to eLH and hCG. Deletion of the C-terminal extension from eLH␤ and hCG␤ by mild acid hydrolysis [2, 3] and by mutation of recombinant hCG␤ [4, 5] had little effect on the in vitro biological activities of the truncated eLH, hCG, and recombinant hCG derivatives. These results led to the conclusion that the C-terminal extension only affected the activities of these hormones in vivo. Prolonged circulatory survival and enhanced in vivo potency following introduction of the CTP into both LH and FSH have been experimentally confirmed [6, 7] . However, truncation of the hCG␤ C-terminus by site-directed mutagenesis affected Nlinked oligosaccharide processing, thereby revealing an intracellular function associated with this structural element [30, 31] . The results reported herein were consistent with recent studies involving eCG isoforms, which revealed that the high degree of O-glycosylation associated with eCG-H reduced its LH and FSH receptor-binding activity [8] . In the present study, we demonstrated that differences in O-glycosylation between eLH and eCG accounted for the eCG␤ subunit contribution to the reduced LH receptorbinding activity of eCG. This result was not demonstrated in a straightforward manner. Progressively increased amounts of unassociated eLH␤ present in hybrid hormone preparations, eLH␣:eLH␤, eFSH␣:eLH␤, and eCG␣:eLH␤, combined with the inhibitory effects of increased ␣Asn 56 oligosaccharide size to suggest that ␣Asn 56 oligosaccharide size was the only factor responsible for the reduced LH receptor-binding activity of eCG, because eCG␣:eLH␤ exhibited the same reduced level of receptor-binding activity. However, the eCG␣:eLH␤ hybrid preparation also possessed the highest content of inactive eLH␤. (For a complete discussion of the ␣Asn 56 oligsoaccharide structures responsible for reduced receptor-binding activity, see Butnev et al. [9] . The present discussion is restricted to the effects of O-glycosylation.) Removal of the C-terminal extension from eLH␤ and eCG␤ permitted separation of the heterodimer from unassociated subunits. When this confounding factor was eliminated, all the truncated ␤ subunit hybrids were at least twofold more active than eCG-L, the most active of the eCG isoforms. Despite the fact that the mass of eLH␤t was 1053 mass units less than that of eCG␤t [9] , the LH receptor-binding activities of hybrids prepared by combining the truncated ␤ subunit preparations with the same ␣ subunit preparation were virtually identical. This result was consistently obtained with all three equine ␣ subunit preparations. The influence of ␤Asn 13 oligosaccharide on receptor-binding activity was probably insignificant because of overall similarities in their overall structures. The most abundant N-linked oligosaccharides obtained from eLH␤ and eCG␤ were biantennary [10, 12] . In the case of eCG␤, these oligosaccharides were quantitatively desialylated by the mild acid treatment [13] , whereas the sulfate moiety in eLH␤ oligosaccharides may have been only partially released because of greater resistance to mild hydrolysis conditions [32] . Even if substantial hydrolysis of the Asn 13 oligosaccharides had occurred, receptor binding should not have been affected. Chemically deglycosylated oLH␤, which possessed only the GlcNAc 2 remnant of the Asn 13 oligosaccharide, combined with intact oLH␣ to produce an oLH derivative with the same LH receptor-binding activity as intact oLH [33] . The most likely explanation for the ␤ subunit contribution to the reduced LH receptor-binding activity of eCG as compared with eLH was differential O-glycosylation of C-terminal residues 121-149. This differential O-glycosylation could have been the result of utilization of more potential glycosyation sites in eCG␤ as compared with eLH␤, a greater occupancy of glycosylation sites in eCG␤ than in eLH␤, or larger oligosaccharides attached to eCG␤ than to eLH␤.
Qualitative assessment of O-glycosylation revealed 12 O-glycosylation sites in both hormones, a surprisingly large number (Fig. 8) [13] or yield of O-linked oligosaccharide [10] greatly underestimated the actual number because of the partial glycosylation observed in the present study.
Quantitative estimates of the extent of glycosylation at individual Ser or Thr residues was absolutely dependent on accurate determination of the repetitive yield obtained during automated Edman degradation. Accordingly, these estimates were restricted to 10 of the 12 glycosylation sites that could be assessed in the course of experiments involving CTP-121-149. Fortunately, estimates for Ser 118 and Ser 149 could be obtained by other means. In both eLH␤ and eCG␤, Ser 118 appeared to be 100% glycosylated based on the difference in galactosamine composition between CTP-100-149 and CTP-121-149 derived from both subunit preparations and the complete resistance of lysine (Lys) 119 to cleavage by trypsin (Fig. 4) . Ser 149 was reportedly 100% glycosylated; carboxypeptidase digestion failed to release any amino acids from eCG␤ and released only isoleucine 146 from 20% of the eLH␤ preparation that lacked the C-terminal tripeptide Lys-Thr-Ser [22, 34] . We encountered extremely low coupling efficiencies when eCG␤ CTP-121-149 was coupled to Sequelon-AA membranes. Because Ser 149 provided the only carboxyl group in the entire peptide, steric hindrance due to carbohydrate attached to its side chain appeared to be responsible for the reduced coupling efficiency. The composition of eLH␤ CTP-140-149 indicated 80% glycosylation of Ser 149 , which was the only glycosylated residue in this peptide preparation.
Extensive analysis of CTP-121-149 revealed a higher percentage of glycosylation in eCG␤ than was observed at four positions: Thr 133 , Ser 137 , and especially Ser 140 and Ser 141 (Fig. 8) . Similar levels of glycosylation in both proteins were observed at the remaining O-linked sites. Despite the dibasic residues separating Ser 137 from Ser 140 , these oligosaccharides largely protected eCG␤ from digestion with trypsin or any other protease [34] . Thus, limited proteolysis is unlikely to provide eCG␤ derivatives that could be used to determine if the greater extent of glycosylation at Ser 140 and Ser 141 contributed to the reduced receptor-binding activity of eCG.
Oligosaccharide size was another major difference between eCG␤ O-glycosylation and eLH␤ O-glycosylation. Although eLH␤ appeared to possess only core type 2 oligosaccharides, consisting of GalNAc, GlcNAc, galactosamine, and sialic acid, eCG␤ O-linked oligosaccharides had a very high content of GlcNAc and galactosamine. This finding was consistent with the presence of lactosamine repeats in eCG␤ O-linked oligosaccharides [28] . Some of these lactosamine repeats have been found to be sensitive to endo-␤-galactosidase digestion, particularly those in eCG-L and eCG-M. These repeats affected both the appearance and the electrophoretic mobility of the eCG␤ band following SDS-PAGE under reducing conditions [8] . For example, the molecular weight of the major eCG␤ band decreased from 40 000-50 000 to 35 000. However, glycosidase-sensitive lactosamine repeats were not entirely responsible for the differences in O-glycosylation between eLH and eCG ␤ subunits. Although the more active eCG preparations, eCG-L and eCG-M, almost doubled their FSH receptor-binding activities and eCG-H tripled its activity, they all remained lower in activity than eLH [8] . Future studies will have to be directed at characterizing the structures of oligosaccharides found at individual glycosylation sites to identify the functionally significant differences between eLH and eCG. Their location on adjacent residues will make this task very difficult because conventional glycopeptide isolation techniques cannot be employed.
Comparison of the primate and equid CG␤ amino acid sequences indicated an overall similarity in glycosylation patterns within each group, with more species-specific differences in the primate sequences (Fig. 9) . Human CG␤ is N-glycosylated at Asn 13 and Asn 30 . Baboon CG␤ possesses both potential glycosylation sites, and the predicted macaque CG␤ amino acid sequence lacks the Asn 13 glycosylation site but substitutes a potential N-glycosylation site at the location of O-glycosylated Ser 127 in hCG␤. The horse LH/CG␤ subunits are N-glycosylated only at Asn 13 [22, 34] . The predicted sequences for the donkey and zebra LH/ CG␤ subunits indicate the same pattern of N-glycosylation. O-glycosylation of hCG␤ Ser residues 121, 127, 132, and 138 has been experimentally defined by several laboratories [35] [36] [37] . The predicted amino acid sequences for baboon and macaque CG␤ subunits suggest the baboon CG␤ possesses three of the four O-glycosylation sites found in hCG␤. The sequence for the macaque CG␤ differed at three sites, including substitution of an N-glycosylation consensus sequence at one position where hCG␤ is O-glycosylated. The zebra and horse ␤ subunit sequences were 95% identical with the zebra LH/CG␤ subunit possessing the same Ser and Thr residues as the horse. There was only one difference between the horse and donkey LH/CG␤ subunit sequences that could affect O-glycosylation. The predicted donkey sequence included cysteine (Cys) instead of Ser 118 . In view of the otherwise strict conservation of potential O-glycosylation sites and because of the potential for intermolecular cross-linking by disulfide bonds involving this single Cys residue, this possible substitution should be examined further. A single base change would convert the TGT sequence found in the donkey [38] to the TCT sequence found in the horse [39] . Therefore, this difference in amino acids may be a sequencing artifact. Sequence conservation beyond Cys 110 is low in the glycoprotein hormone family. Typical of that, the primate CG␤ sequences showed only 50-71% sequence identity when residues 111-145 were compared. In contrast, the equid LH/CG␤ subunit C-terminal sequences were 92-97% identical, suggesting an important role for O-linked carbohydrate in these species. Chorionic gonadotropins have arisen twice during evolution. In the primates, gene duplication produced a CG␤ gene that incorporated a C-terminal extension as well as other mutations in the core ␤ subunit [40] . In the equids, a single LH/CG␤ subunit gene is expressed in both pituitary and placenta, producing LH and CG, respectively [39] . The human ligands for the LH receptor differ at both the protein (80% identity over residues 1-121) and carbohydrate levels. Their equine counterparts are distinguished only by their carbohydrate moieties; however, the horse LH receptor is at least fivefold more sensitive to glycosylation differences [41] .
